ChemicalBook >> CAS DataBase List >>Trastuzumab

Trastuzumab

CAS No.
180288-69-1
Chemical Name:
Trastuzumab
Synonyms
Herceptin;Trastuzumab Beta;RhuMab HER2;TRASTUZUMAB 95 % +;TRASTUZUMAB 98 % +;Trastuzumab USP/EP/BP;TrastuzuMab(Herceptin);Trastuzumab (anti-HER2);Trastuzumab,Stock solution;Trastuzumab - 20mg/ml in PBS
CBNumber:
CB61074602
Molecular Formula:
C10H14N6O5
Molecular Weight:
298.25536
MDL Number:
MFCD03702625
MOL File:
180288-69-1.mol
Last updated:2023-05-21 10:59:17

Trastuzumab Properties

storage temp. Store at -20°C
NCI Dictionary of Cancer Terms Herceptin
FDA UNII P188ANX8CK
NCI Drug Dictionary Herceptin

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS08
Signal word  Danger
Hazard statements  H360

Trastuzumab price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Biosynth Carbosynth FT65040 Trastuzumab - 20mg/ml in PBS 180288-69-1 1mg $78 2021-12-16 Buy
Biosynth Carbosynth FT65040 Trastuzumab - 20mg/ml in PBS 180288-69-1 2mg $120 2021-12-16 Buy
ChemScene CS-7821 Trastuzumab 99.30% 180288-69-1 1mg $192 2021-12-16 Buy
Biosynth Carbosynth FT65040 Trastuzumab - 20mg/ml in PBS 180288-69-1 5mg $240 2021-12-16 Buy
Biosynth Carbosynth FT65040 Trastuzumab - 20mg/ml in PBS 180288-69-1 10mg $420 2021-12-16 Buy
Product number Packaging Price Buy
FT65040 1mg $78 Buy
FT65040 2mg $120 Buy
CS-7821 1mg $192 Buy
FT65040 5mg $240 Buy
FT65040 10mg $420 Buy

Trastuzumab Chemical Properties,Uses,Production

Uses

Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer.

Indications

The introduction of herceptin (Trastuzumab) into clinical practice for the treatment of breast cancer marks a major advance in the use of monoclonal antibody cancer therapy. Herceptin is a humanized antibody directed against the HER-2 antigen that is overexpressed on the tumor cell surface in approximately 25% of breast cancer patients. HER-2/neu/erbB2 overexpression marks an aggressive estrogen receptor–negative form of breast cancer. Therefore, a therapeutic agent selective for this target is particularly valuable. Herceptin is administered by intravenous infusion and in conjunction with paclitaxel can extend survival in patients with HER-2/neu/erbB2 overexpressing metastatic breast cancer.Herceptin use is associated with infusion- related hypotension, flushing and bronchoconstriction, and skin rash but no bone marrow toxicity. Herceptin appears to sensitize patients to cardiotoxicity, an important concern in patients also receiving doxorubicin.

Definition

Herceptin (generic name: trastuzumab) is not a chemo drug, it is a targeted therapy anticancer drug.
Herceptin contains one active ingredient, trastuzumab, and is given as an intravenous (IV) infusion slowly into a vein. Herceptin Hylecta contains two active ingredients, trastuzumab and hyaluronidase-oysk, and is given as a subcutaneous injection, which is an injection that goes under the skin.

Mechanism of action

Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to an extracellular domain of this receptor and inhibits HER2 homodimerization, thereby preventing HER2-mediated signaling. It is also thought to facilitate antibody-dependent cellular cytotoxicity, leading to the death of cells that express HER2. Its mechanism differs slightly from that of the newer agent pertuzumab; the latter inhibits hetero-dimerization of HER2 with HER3, a related growth factor receptor. Trastuzumab has been shown to bind three distinct regions of domain IV of the HER2 extracellular domain through electrostatic and hydrophobic bindings[1].

References

[1] Hamid Maadi. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.” Cancers (2021).

Trastuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 104)Suppliers
Supplier Tel Email Country ProdList Advantage
Shanghai Minbiotech Co., Ltd.
+8617315815539 sales@minbiotech.com CHINA 129 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21689 55
SHANDONG ZHI SHANG CHEMICAL CO.LTD
+86 18953170293 sales@sdzschem.com China 2931 58
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 967 58
Hubei xin bonus chemical co. LTD
86-13657291602 linda@hubeijusheng.com CHINA 22968 58
career henan chemical co
+86-0371-86658258 15093356674; factory@coreychem.com China 29826 58
Hubei Ipure Biology Co., Ltd
+8613367258412 ada@ipurechemical.com China 10326 58
HONG KONG IPURE BIOLOGY CO.,LIMITED
86 18062405514 18062405514 ada@ipurechemical.com CHINA 3465 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250 1026@dideu.com China 28302 58
AFINE CHEMICALS LIMITED
0571-85134551 18958018566; info@afinechem.com China 15377 58

Related articles

View Lastest Price from Trastuzumab manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Trastuzumab pictures 2023-01-11 Trastuzumab
180288-69-1
US $0.00 / G 1G 98%min 30kg/month WUHAN FORTUNA CHEMICAL CO., LTD
Trastuzumab USP/EP/BP pictures 2021-07-03 Trastuzumab USP/EP/BP
180288-69-1
US $1.10 / g 1g 99.9% 100 Tons Min Dideu Industries Group Limited
Trastuzumab pictures 2020-05-03 Trastuzumab
180288-69-1
US $0.00-0.00 / Kg 1KG 99.0% 800 ton Shaanxi Dideu Medichem Co. Ltd
  • Trastuzumab pictures
  • Trastuzumab
    180288-69-1
  • US $0.00 / G
  • 98%min
  • WUHAN FORTUNA CHEMICAL CO., LTD
  • Trastuzumab pictures
  • Trastuzumab
    180288-69-1
  • US $0.00-0.00 / Kg
  • 99.0%
  • Shaanxi Dideu Medichem Co. Ltd
TrastuzuMab(Herceptin) TRASTUZUMAB 98 % + IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer TRASTUZUMAB 95 % + Anti HER2, Ig gamma-1 chain C region Recombinant humanized anti-HER2 antibody RhuMab HER2 Trastuzumab - 20mg/ml in PBS Trastuzumab,Stock solution Trastuzumab (anti-HER2) Trastuzumab USP/EP/BP Herceptin Trastuzumab Beta Research Grade Trastuzumab(DHC09601) EGFR,Trastuzumab,Anti-Human HER2, Humanized Antibody,Epidermal growth factor receptor,HER1,inhibit,ErbB-1,Inhibitor Anti-Human HER2, Humanized Antibody 180288-69-1